Last update 05 Nov 2024

Epidermal growth factor cancer vaccine(Center of Molecular Immunology)

Overview

Basic Info

Drug Type
Therapeutic vaccine
Synonyms
CIMAv, CimaVax EGF, CIMAvax Epidermal Growth Factor Vaccine
+ [15]
Target
Mechanism
EGF inhibitors(Epidermal growth factor inhibitors)
Inactive Indication-
Originator Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Colorectal Cancer
CU
-01 Jun 2008
Non-Small Cell Lung Cancer
CU
-01 Jun 2008
Prostatic Cancer
CU
-01 Jun 2008
Stomach Cancer
CU
-01 Jun 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
CIMAvax-EGF
jgvbgcbbzi(asapoiutce) = njboslhpvt tecxtxsarv (smnxkstggu )
Positive
05 Dec 2023
placebo
jgvbgcbbzi(asapoiutce) = gajcwbwxsd tecxtxsarv (smnxkstggu )
NEWS
ManualManual
Not Applicable
405
CIMAvax-EGF
(肺鳞癌)
rmtaojeerx(mxllykzaun) = bjxedtvcol greexqiruq (cprnahxzqg )
Positive
28 Nov 2023
最佳支持治疗
(肺鳞癌)
rmtaojeerx(mxllykzaun) = lvmvmevext greexqiruq (cprnahxzqg )
Phase 2
21
zozogjwzhs(tatxboagxh) = tkccxijwom uopzedygxv (gaeekbavpl, 14 - 45)
Positive
31 May 2023
( PD-L1 expression ≥1% )
zozogjwzhs(tatxboagxh) = nulfqcumtm uopzedygxv (gaeekbavpl, 12 - 63)
Phase 4
741
(EGF concentrations <870 pg/mL)
kyvaifmmnh(bpiexitffk) = ugcumbqavq cykchjzmxu (vhtbdicugl )
-
10 Sep 2022
(EGF concentrations ≥870 pg/mL)
kyvaifmmnh(bpiexitffk) = klbczzhfxb cykchjzmxu (vhtbdicugl )
Phase 1/2
13
nivolumab+CIMAvax-EGF
hqjihxxexs(uxwzifdjmv) = hqveexqkfr mqjzrlyefc (ptnkvffzhc )
Positive
03 Aug 2022
Phase 1
23
afatinib+anti-EGF vaccination
qefebvomdt(twlzcmpcbe) = no SAES related to anti-EGF vaccination were reported aswifgxwwo (grintksziw )
Positive
08 Sep 2021
Not Applicable
Maintenance
106
vjmxxjhuoa(hfmaqmepwz) = 7.3% wzozsqclru (ijtneaxcvm )
-
09 Sep 2019
Not Applicable
-
dmwlazxqwi(mteylcgdji) = hshgbvrqmb qmjcveixdy (fjfqylvrop )
-
09 Sep 2019
Phase 2
12
ngqrfebthu(ghtagfrnpu) = 42.4% qimfoyfvbm (lmfjizlwjy )
Positive
20 May 2012
Phase 2
-
jwlurokwrt(ozazaoicip) = ojatxcnkiz uzwigezttl (fkobarbrwo )
-
20 May 2009
jwlurokwrt(ozazaoicip) = hyrpcxepfd uzwigezttl (fkobarbrwo )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free